Artivion, Inc. (NYSE:AORT) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Artivion, Inc. (NYSE:AORT) have been assigned an average rating of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $43.1333.

A number of equities research analysts have recently issued reports on AORT shares. Needham & Company LLC upped their target price on shares of Artivion from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a report on Saturday, September 27th. Stifel Nicolaus increased their price target on shares of Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a report on Monday, September 29th. Canaccord Genuity Group increased their price target on shares of Artivion from $41.00 to $50.00 and gave the company a “buy” rating in a report on Monday, September 29th. Finally, LADENBURG THALM/SH SH cut shares of Artivion from a “buy” rating to a “neutral” rating and increased their price target for the company from $32.00 to $38.80 in a report on Wednesday, August 13th.

Artivion Trading Up 1.2%

Shares of NYSE:AORT opened at $41.09 on Friday. The company’s 50-day moving average price is $40.36 and its two-hundred day moving average price is $31.96. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. Artivion has a one year low of $21.97 and a one year high of $45.07. The stock has a market capitalization of $1.94 billion, a PE ratio of -97.83 and a beta of 1.67.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.11 by $0.13. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The firm had revenue of $112.97 million for the quarter, compared to analysts’ expectations of $107.96 million. Artivion’s revenue for the quarter was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Artivion will post 0.37 EPS for the current fiscal year.

Insider Activity at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 18,200 shares of the stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $44.02, for a total transaction of $801,164.00. Following the transaction, the senior vice president owned 64,200 shares in the company, valued at $2,826,084. This represents a 22.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John E. Davis sold 10,802 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $43.67, for a total transaction of $471,723.34. Following the transaction, the insider owned 208,778 shares in the company, valued at approximately $9,117,335.26. The trade was a 4.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold 74,858 shares of company stock valued at $3,250,129 in the last 90 days. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP grew its position in shares of Artivion by 4.1% during the 1st quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company’s stock worth $42,460,000 after purchasing an additional 67,327 shares in the last quarter. Next Century Growth Investors LLC boosted its position in shares of Artivion by 107.6% during the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock worth $25,140,000 after acquiring an additional 530,122 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Artivion by 22.8% during the 2nd quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock worth $20,062,000 after acquiring an additional 119,634 shares in the last quarter. Invesco Ltd. boosted its position in shares of Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after acquiring an additional 139,370 shares in the last quarter. Finally, Lord Abbett & CO. LLC boosted its position in shares of Artivion by 31.0% during the 1st quarter. Lord Abbett & CO. LLC now owns 401,904 shares of the company’s stock worth $9,879,000 after acquiring an additional 95,202 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.